| Literature DB >> 24843430 |
Ji Yun Jeong1, Jung-Guk Kim1, Bo-Wan Kim1, Seong Su Moon1, Hye-Soon Kim2, Keun-Gyu Park2, Kyu Chang Won3, Hyoung Woo Lee3, Ji Sung Yoon3, Ho-Sang Shon4, Ji Hyun Lee4, Eui-Dal Jung4, Mi Young Park5, Byung-Yeol Chun6, Keon-Yeop Kim6, Tae-Yoon Hwang7, Mi-Young Lee8, In-Kyu Lee9.
Abstract
UNLABELLED: Aims/Introduction: This study determined the change in prevalence of diabetes and prediabetes over a period of 5 years in South Korea. The incidence of diabetes and prediabetes and risk factors associated with the development of diabetes were also investigated.Entities:
Keywords: Diabetes mellitus; Prevalence; South Korea
Year: 2010 PMID: 24843430 PMCID: PMC4020719 DOI: 10.1111/j.2040-1124.2010.00045.x
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Prevalence of diabetes and prediabetes in Dalseong population‐based cohort survey (2003–2008)
| 2003 | 2008 | |||
|---|---|---|---|---|
| Prevalence (%) | ||||
| Prediabetes | Diabetes | Prediabetes | Diabetes | |
| Men | ||||
| Age (years) | ||||
| ≤39 | 25.5 | 2.1 | 14.3 | 0 |
| 40–49 | 31.3 | 4.5 | 40.4 | 8.5 |
| 50–59 | 27.6 | 11.5 | 35.8 | 16.4 |
| 60–69 | 25.5 | 18.4 | 29.0 | 21.9 |
| ≥70 | 22.4 | 15.8 | 32.8 | 24.6 |
| Total | 26.3 | 12.8 | 32.8 | 20.1 |
| Adjusted† | 27.0 | 6.4 | 35.47 | 8.0 |
| Women | ||||
| Age (years) | ||||
| ≤39 | 6.5 | 2.6 | 14.3 | 0 |
| 40–49 | 13.3 | 5.6 | 22.5 | 10.8 |
| 50–59 | 23.9 | 9.3 | 26.6 | 16.3 |
| 60–69 | 23.7 | 14.5 | 30.0 | 25.2 |
| ≥70 | 20.8 | 17.3 | 35.8 | 24.9 |
| Total | 20.2 | 11.5 | 30.0 | 21.1 |
| Adjusted† | 13.8 | 6.9 | 25.0 | 9.9 |
| Total | ||||
| Age (years) | ||||
| ≤39 | 13.7 | 2.4 | 14.3 | 0 |
| 40–49 | 19.9 | 5.2 | 28.2 | 10.1 |
| 50–59 | 25.4 | 10.2 | 30.3 | 16.3 |
| 60–69 | 24.3 | 15.9 | 29.6 | 24.0 |
| ≥70 | 21.5 | 16.6 | 34.6 | 24.8 |
| Total | 22.5 | 12.0 | 31.1 | 20.8 |
| Adjusted† | 18.5 | 6.7 | 28.4 | 9.1 |
†Age‐adjusted prevalence.
Prevalence of prediabetes in Dalseong population‐based cohort survey (2003–2008)
| 2003 | 2008 | |||
|---|---|---|---|---|
| Prevalence (%) | ||||
| IFG† | IGT‡ | IFG† | IGT‡ | |
| Men | ||||
| Age (years) | ||||
| ≤39 | 21.3 | 7.0 | 14.3 | 14.3 |
| 40–49 | 29.7 | 4.5 | 29.8 | 21.7 |
| 50–59 | 25.3 | 4.7 | 29.9 | 12.1 |
| 60–69 | 20.8 | 6.2 | 19.2 | 16.5 |
| ≥70 | 17.2 | 11.4 | 17.9 | 22.0 |
| Total | 22.6 | 6.8 | 22.2 | 17.8 |
| Adjusted§ | 23.6 | 6.2 | 21.0 | 16.4 |
| Women | ||||
| Age (years) | ||||
| ≤39 | 6.5 | 1.3 | 14.3 | 14.3 |
| 40–49 | 10.8 | 6.3 | 12.7 | 15.5 |
| 50–59 | 20.2 | 6.6 | 15.8 | 17.1 |
| 60–69 | 19.9 | 8.7 | 20.6 | 18.5 |
| ≥70 | 15.8 | 10.5 | 20.3 | 23.6 |
| Total | 16.7 | 7.6 | 18.5 | 19.4 |
| Adjusted§ | 11.8 | 4.9 | 15.4 | 16.3 |
| Total | ||||
| Age (years) | ||||
| ≤39 | 12.1 | 3.4 | 14.3 | 14.3 |
| 40–49 | 17.7 | 5.7 | 18.1 | 17.5 |
| 50–59 | 22.3 | 5.8 | 21.4 | 15.1 |
| 60–69 | 20.2 | 7.8 | 20.1 | 17.8 |
| ≥70 | 16.4 | 10.9 | 19.4 | 23.0 |
| Total | 19.0 | 7.3 | 19.9 | 18.8 |
| Adjusted§ | 16.0 | 5.3 | 17.2 | 16.2 |
†Impaired fasting glucose, ‡Impaired glucose tolerance, §Age‐adjusted prevalence.
Figure 1Cumulative incidence rate of subjects with normal glucose tolerance or prediabetes to those with diabetes according to their age group over 5 years (2003–2008).
Figure 2Cumulative incidence rate of subjects with normal glucose tolerance to those with prediabetes according to their age group over 5 years (2003–2008).
Baseline characteristics of the study population according to incident diabetes status (2003–2008)
| No. subjects | No. incident diabetes | Incident diabetes |
|
|---|---|---|---|
| 1006 | 135 | ||
| Age (years) | 58 ± 11 | 61 ± 9 | 0.002 |
| Systolic BP (mmHg) | 130 ± 18 | 139 ± 21 | <0.001 |
| Diastolic BP (mmHg) | 82 ± 11 | 87 ± 12 | <0.001 |
| HbA1c (%) | 5.3 ± 0.6 | 5.7 ± 0.5 | 0.111 |
| Body mass index (kg/m2) | 23.5 ± 3.1 | 24.6 ± 3.2 | <0.001 |
| Waist circumference (cm) | 81.7 ± 8.7 | 84.0 ± 8.8 | <0.001 |
| Waist‐to‐hip ratio | |||
| Male | 0.87 ± 0.07 | 0.92 ± 0.06 | 0.003 |
| Female | 0.87 ± 0.07 | 0.90 ± 0.06 | <0.001 |
| AST (IU/L) | 24 ± 14 | 29 ± 21 | 0.017 |
| ALT (IU/L) | 37 ± 13 | 42 ± 25 | 0.028 |
| Cholesterol (mg/dL) | 197 ± 36 | 204 ± 37 | 0.023 |
| Triglyceride (mg/dL) | 150 ± 111 | 192 ± 139 | 0.001 |
| HDL cholesterol (mg/dL) | 52 ± 13 | 53 ± 23 | 0.456 |
| LDL cholesterol (mg/dL) | 115 ± 35 | 112 ± 41 | 0.463 |
| γGT (IU/L) | 28 ± 46 | 44 ± 45 | 0.003 |
| hsCRP (mg/L) | 1.28 ± 2.21 | 2.16 ± 3.67 | 0.028 |
| Parental diabetes history (%) | 5.5 | 6.8 | 0.862 |
| Smoking Current smoker | 23.1 | 26.2 | 0.375 |
| Ex‐smoker | 13.3 | 16.4 | |
| Never‐smoker | 65.3 | 57.5 | |
ALT, alanine transferase; AST, aspartate transaminase; BP, blood pressure; HDL, high‐density lipoprotein; hsCRP, high‐sensitivity C‐reactive protein; LDL, low‐density lipoprotein; γGT, γ‐glutamyl‐transpeptidase.
Adjusted odds ratios (95% confidence intervals) of developing diabetes including impaired fasting glucose and impaired glucose tolerance obtained from logistic regression analysis (2003–2008)
| Odds ratio |
| 95% CI† | |
|---|---|---|---|
| Impaired fasting glucose | 5.661 | <0.001 | 3.442–9.308 |
| Impaired glucose tolerance | 6.013 | <0.001 | 3.225–11.213 |
| Age (years) | 1.013 | 0.047 | 1.000–1.063 |
| Waist‐to‐hip ratio | 1.513 | 0.049 | 1.002–2.285 |
†This model was adjusted for systolic blood pressure, diastolic blood pressure, body mass index, aspartate transaminase, alanine aminotransferase, total cholesterol, triglyceride, γ‐glutamyl‐transpeptidase and high‐sensitivity C‐reactive protein. CI, confidence intervals.
Adjusted odds ratios (95% confidence intervals) of developing diabetes excluding impaired fasting glucose and impaired glucose tolerance obtained from logistic regression analysis (2003–2008)
| Odds ratio |
| 95% CI† | |
|---|---|---|---|
| Systolic blood pressure (mmHg) | 1.023 | <0.001 | 1.010–1.035 |
| hsCRP (mg/dL) | 1.097 | 0.008 | 1.024–1.174 |
| Triglyceride (mg/dL) | 1.002 | 0.023 | 1.000–1.035 |
| Waist‐to‐hip ratio | 1.696 | 0.007 | 1.154–2.492 |
†This model was adjusted for age, diastolic blood pressure, body mass index, aspartate transaminase, alanine aminotransferase, total cholesterol, γ‐glutamyl‐transpeptidase. CI, confidence intervals.